Malaria: Prevention in travellers

BMJ

Volumn 321, Issue 7254, 2000, Pages 154-160

  Croft, Ashley ^a  

^a MINISTRY OF DEFENCE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ANTIMALARIAL AGENT; ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; DIETHYLTOLUAMIDE; DOXYCYCLINE; FANSIDAR; INSECT REPELLENT; INSECTICIDE; MALARIA VACCINE; MALOPRIM; MEFLOQUINE; PROGUANIL;

AGRANULOCYTOSIS; AIR CONDITIONING; BED NET; BIOLOGICAL PEST CONTROL; COUGHING; DIARRHEA; ERYTHEMA MULTIFORME; FATIGUE; GROWTH DISORDER; HEADACHE; HUMAN; INFLAMMATION; INSOMNIA; LIVER TOXICITY; MALARIA; MALARIA CONTROL; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROTECTIVE CLOTHING; PRURITUS; RASH; REVIEW; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TRAVEL; VACCINATION; VAGINITIS; VERTIGO; VOMITING;

ADULT; ANTIMALARIALS; CHILD; FEMALE; HUMANS; INSECTICIDES; MALARIA; MALE; MOSQUITO CONTROL; TRAVEL;

EID: 0034661805     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.321.7254.154     Document Type: Article

References (84)

1. White NJ. Malaria. In: CookGC,ed. Manson's tropical diseases. 20th ed. London: Saunders, 1996: 1087–1164.
2. World Health Organization. The world health report 1997. Conquering suffering, enriching humanity. Geneva: WHO Office of Information, 1997.
3. Murphy GS, Oldfield EC. Falciparum malaria. Infect Dis Clin North Am 1996; 10: 747–755.
4. Kain KC, Keystone JS. Malaria in travelers. Epidemiology, disease and prevention. Infect Dis Clin North Am 1998; 12: 267–284.
5. Lobel HO, Kozarsky PE. Update on prevention of malaria for travelers. JAMA 1997; 278: 1767–1771.
6. Winstanley P. Malaria: treatment. J R Coll Physicians Lond 1998; 32: 203–207.
7. Baudon D, Martet G. Paludisme et voyageurs: protection et information. Med Trop (Mars) 1997; 57: 497–500.
8. Health information for international travel, 1996–97. Atlanta: US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Infectious Diseases, Division of Quarantine, 1997. (HHS publication No 95:8280.)
9. Bradley DJ, Warhurst DC. Guidelines for the prevention of malaria in travellers from the United Kingdom. Commun Dis Rep CDR Rev 1997; 7: R137–R152.
10. Krogstad DJ. Malaria as a reemerging disease. Epidemiol Rev 1996; 18: 77–89.
11. Olsen VV. Principielle overvejelser vedrørende malariaprofylakse. Ugeskr Læger 1998; 160: 2410–2411.
12. Miller SA, Bergman BP, Croft AM. Epidemiology of malaria in the British Army from 1982–1986. J R Army Med Corps 1999; 145: 20–22.
13. Beier JC, Oster CN, Onyango FK, et al. Plasmodium falciparum incidence relative to entomological inoculation rates at a site proposed for testing malaria vaccines in western Kenya. Am J Trop Med Hyg 1994; 50: 529–536.
14. Schoepke A, Steffen R, Gratz N. Effectiveness of personal protection measures against mosquito bites for malaria prophylaxis in travelers. J Travel Med 1998; 128: 931–940.
15. Fradin MS. Mosquitoes and mosquito repellents: a clinician's guide. Ann Intern Med 1998; 128: 931–940.
16. Hewitt SE, Farhan M, Urhaman H, et al. Self-protection from malaria vectors in Pakistan: an evaluation of popular existing methods and appropriate new techniques in Afghan refugee communities. Ann Trop Med Parasitol 1996; 90: 337–344.
17. Service MW. Mosquito ecology: field sampling methods. 2nd ed. London: Chapman and Hall, 1993.
18. Nasci RS, Harris CW, Porter CK. Failure of an insect electrocuting device to reduce mosquito biting. Mosquito News 1983; 43: 180–183.
19. Lewis DJ, Fairchild WL, Leprince DJ. Evaluation of an electronic mosquito repeller. Can Entomol 1982; 114: 699–702.
20. Yap HH, Tan HT, Yahaya AM, et al. Field efficacy of mosquito coil formulations containing d-allethrin and d-transallethrin against indoor mosquitoes especially Culex quinquefasciatus Say. Southeast Asian J Trop Med Public Health 1990; 21: 558–563.
21. Vernède R, van Meer MMM, Aplers MP. Smoke as a form of personal protection against mosquitos, a field study in Papua New Guinea. Southeast Asian J Trop Med Public Health 1994; 25: 771–775.
22. Lengeler C. Insecticide treated bednets and curtains for preventing malaria.In: Cochrane Collaboration, ed.Cochrane Library. Issue 4.Oxford: Update Software, 1999.
23. Carnevale P, Mouchet J. La protection individuelle contre les insectes vecteurs. Med Trop (Mars) 1997; 57: 505–510.
24. Insect repellents. Med Lett Drugs Ther 1989; 31: 45–47.
25. Lillie TH, Schreck CE, Rahe AJ. Effectiveness of personal protection against mosquitoes in Alaska. J Med Entomol 1988; 25: 475–478.
26. Juckett G. Malaria prevention in travelers. Am Fam Physician 1999; 59: 2523–2530.
27. Alexander B, Cadena H, Usma MC, et al. Laboratory and field evaluations of a repellent soap containing diethyl toluamide (DEET) and permethrin against phlebotomine sand flies (Diptera: Psychodidae) in Valle del Cauca, Colombia. Am J Trop Med Hyg 1995; 52: 169–173.
28. McConnell R, Fidler AT, Chrislip D. Everglades National Park health hazard evaluation report. In:Cincinnati, OH: US Department of Health and Human Services, Public Health Service, 1986. (NIOSH health hazard evaluation report No HETA-83–085-1757.)
29. Lamberg SI, Mulrennan JA. Bullous reaction to diethyl toluamide (DEET) resembling a blistering insect eruption. Arch Dermatol 1969; 100: 582–586.
30. Curtis CF, Townson H. Malaria: existing methods of vector control and molecular entomology. Br Med Bull 1998; 54: 311–325.
31. Stemberger H, Leimer R, Widermann G. Tolerability of long-term prophylaxis with Fansidar: a randomized double-blind study in Nigeria. Acta Trop 1984; 41: 391–399.
32. Petersen E. Malariaprofylakse. Ugeskr Læger 1997; 159: 2723–2730.
33. Croft A, Garner P. Mefloquine to prevent malaria: a systematic review of trials. BMJ 1997; 315: 1412–1416.
34. Mefloquine and malaria prophylaxis. Drug Ther Bull 1998; 36: 20–22.
35. Gherardin T. Mefloquine as malaria prophylaxis. Aust Fam Physician 1999; 28: 310.
36. Schlagenhauf P. Mefloquine for malaria chemoprophylaxis 1992–1998: a review. J Travel Med 1999; 6: 122–133.
37. Fogh S, Schapira A, Bygbjerg IC, et al. Malaria chemoprophylaxis in travellers to east Africa: a comparative prospective study of chloroquine plus proguanil with chloroquine plus sulfadoxine-pyrimethamine. BMJ 1988; 296: 820–822.
38. Wetsteyn J.C.F.M., de Geus A. Comparison of three regimens for malaria prophylaxis in travellers to east, central, and southern Africa. BMJ 1993; 307: 1041–1043.
39. Drysdale SF, Phillips-Howard PA, Behrens RH. Proguanil, chloroquine, and mouth ulcers. Lancet 1990; 335: 164.
40. Ohrt C, Richie TL, Widjaja H, et al. Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997; 126: 963–972.
41. Taylor WR, Richie TL, Fryauff DJ, et al. Malaria prophylaxis using azithromycin: a double-blind, placebo-controlled trial in Irian Jaya, Indonesia. Clin Infect Dis 1999; 28: 74–81.
42. Phillips MA, Kass RB. User acceptability patterns for mefloquine and doxycycline malaria chemoprophylaxis. J Travel Med 1996; 3: 40–45.
43. Leutscher PDC. Malariaprofylakse. Ugeskr Læger 1997; 159: 4866–4867.
44. Croft AMJ, Garner P. Mefloquine for preventing malaria in non-immune adult travellers.In: Cochrane Collaboration, ed.Cochrane Library. Issue 4.Oxford: Update Software, 1999.
45. Barrett PJ, Emmins PD, Clarke PD, Bradley DJ. Comparison of adverse events associated with use of mefloquine and combinations of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers. BMJ 1996; 313: 525–528.
46. Dolmans WMV, van der Kaay HJ, Leentvaar-Kuijpers A, et al. Malariaprofylaxe: adviezen wederom aangepast. Ned Tijdschr Geneeskd 1996; 140: 892–893.
47. Smith HR, Croft AM, Black MM. Dermatological adverse effects with the antimalarial drug mefloquine: a review of 74 published case reports. Clin Exp Derm 1999; 24: 249–254.
48. Bem L, Kerr L, Stuerchler D. Mefloquine prophylaxis: an overview of spontaneous reports of severe psychiatric reactions and convulsions. J Trop Med Hyg 1992; 95: 167–169.
49. Huzly D, Schönfeld C, Beurle W, et al. Malaria chemoprophylaxis in German tourists: a prospective study on compliance and adverse reactions. J Travel Med 1996; 3: 148–155.
50. Schlagenhauf P, Steffen R, Lobel H, et al. Mefloquine tolerability during chemoprophylaxis: focus on adverse event assessments, stereochemistry and compliance. Trop Med Int Health 1996; 1: 485–494.
51. Handschin JC, Wall M, Steffen R, et al. Tolerability and effectiveness of malaria chemoprophylaxis with mefloquine or chloroquine with or without co-medication. J Travel Med 1997; 4: 121–127.
52. Van Riemsdijk MM, van der Klauw MM, van Heest JAC, et al. Neuro-psychiatric effects of antimalarials. Eur J Clin Pharmacol 1997; 52: 1–6.
53. Mittelholzer ML, Wall M, Steffen R, et al. Malaria prophylaxis in different age groups. J Travel Med 1996; 4: 219–223.
54. Phillips-Howard PA, Björkman AB. Ascertainment of risk of serious adverse reactions associated with chemoprophylactic antimalarial drugs. Bull WHO 1990; 68: 493–504.
55. Ashby D, Smyth RL, Brown PJ. Statistical issues in pharmacoepidemiological case-control studies. Statist Med 1998; 17: 1839–1850.
56. Shanks GD, Edstein MD, Suriyamongkol V, et al. Malaria chemoprophylaxis using proguanil/dapsone combinations on the Thai-Cambodian border. Am J Trop Med Hyg 1992; 46: 643–648.
57. Miller KD, Lobel HO, Satriale RF, et al. Severe cutaneous reactions among American travelers using pyrimethamine-sulfadoxine for malaria prophylaxis. Am J Trop Med Hyg 1986; 35: 451–458.
58. Hatton CSR, Peto TEA, Bunch C, et al. Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet 1986; 1: 411–414.
59. Neftel K, Woodtly W, Schmid M, et al. Amodiaquine induced agranulocytosis and liver damage. BMJ 1986; 292: 721–723.
60. Larrey D, Castot A, Pessayre D, et al. Amodiaquine-induced hepatitis. A report of seven cases. Ann Intern Med 1986; 104: 801–803.
61. Woodtli W, Vonmoos P, Siegrist P, et al. Amodiaquin-induzierte hepatitis mit leukopenie. Schweiz Med Wochenschr 1986; 116: 966–968.
62. Bernuau J, Larrey D, Campillo B, et al. Amodiaquine-induced fulminant hepatitis. J Hepatol 1988; 6: 109–112.
63. Charmot G, Goujon C. Hépatites mineures pouvant être dues à l'amodiaquine. Bull Soc Pathol Exot 1987; 80: 266–270.
64. Raymond JM, Dumas F, Baldit C, et al. Fatal acute hepatitis due to amodiaquine. J Clin Gastroenterol 1989; 11: 602–603.
65. Shanks GD, Edstein MD, Suriyamongkol V, et al. Malaria chemoprophylaxis using proguanil / dapsone combinations on the Thai-Cambodian border. Am J Trop Med Hyg 1992; 46: 643–648.
66. Graves P, Gelbland H. Vaccines for preventing malaria In: Cochrane Collaboration, ed.Cochrane Library. Issue 4.Oxford: Update Software, 1999.
67. Osimitz TG, Murphy JV. Neurological effects associated with use of the insect repellent N,N-diethyl-m-toluamide (DEET). J Toxicol Clin Toxicol 1997; 35: 435–441.
68. De Garbino JP, Laborde A. Toxicity of an insect repellent: N,N-diethyl-m-toluamide. Vet Hum Toxicol 1983; 25: 422–423.
69. Smithuis FM, van Woensel JBM, Nordlander E, et al. Comparison of two mefloquine regimens for treatment of Plasmodium falciparum malaria on the northeastern Thai-Cambodian border. Antimicrob Agents Chemother 1993; 37: 1977–1981.
70. Ter Kuile FO, Dolan G, Nosten F, et al. Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria. Lancet 1993; 341: 1044–1049.
71. Luxemburger C, Price RN, Nosten F, et al. Mefloquine in infants and young children. Ann Trop Paediatr 1996; 16: 281–286.
72. Are insect repellents safe? Lancet 1988; 2: 610–611.
73. Bouchaud O, Longuet C, Coulaud JP. Prophylaxie du paludisme. Rev Prat 1998; 48: 279–286.
74. Cot M, Roisin A, Barro D, et al. Effect of chloroquine chemoprophylaxis during pregnancy on birth weight: results of a randomized trial. Am J Trop Med Hyg 1992; 46: 21–27.
75. Dolan G, ter Kuile FO, Jacoutot V, et al. Bed nets for the prevention of malaria and anaemia in pregnancy. Trans R Soc Trop Med Hyg 1993; 87: 620–626.
76. Garner P, Gülmezoglu AM. Prevention versus treatment for malaria in pregnant women.In: Cochrane Collaboration, ed.Cochrane Library. Issue 4.Oxford: Update Software, 1999.
77. Blomquist L, Thorsell W. Distribution and fate of the insect repellent 14C-N, N-diethyl-m-toluamide in the animal body. II. Distribution and excretion after cutaneous application. Acta Pharmacol Toxicol (Copenh) 1977; 41: 235–243.
78. Osimitz TG, Grothaus RH. The present safety assessment of DEET. J Am Mosquito Control Assoc 1995; 11: 274–278.
79. Samuel BU, Barry M. The pregnant traveler. Infect Dis Clin North Am 1998; 12: 25–354.
80. Schaefer C, Peters PW. Intrauterine diethyltoluamide exposure and fetal outcome. Reprod Toxicol 1992; 6: 175–176.
81. Nosten F, ter Kuile F, Maelankiri L, et al. Mefloquine prophylaxis prevents malaria during pregnancy: a double-blind, placebo-controlled study. J Infect Dis 1994; 169: 595–603.
82. Suh KN, Keystone JS. Malaria prophylaxis in pregnancy and children. Infect Dis Clin Pract 1996; 5: 541–546.
83. Shamiss A, Atar E, Zohar L, Cain Y. Mefloquine versus doxycycline for malaria prophylaxis in intermittent exposure of Israeli Air Force aircrew in Rwanda. Aviat Space Environ Med 1996; 67: 872–873.
84. Schlagenhauf P, Lobel H, Steffen R, et al. Tolerance of mefloquine by Swissair trainee pilots. Am J Trop Med Hyg 1997; 56: 235–240.